|
Description
| DRAXIS Health Inc. (TSX: DAX) (NASDAQ: DRAX), Mississauga, Ont., has received notification from the US Food and Drug Administration (FDA) that the company's manufacturing operations in Montreal, Quebec continue to maintain their classification as acceptable facilities following an extensive inspection by the FDA in January 2007 of all six production and quality systems at DRAXIS Pharma, the contract manufacturing division of DRAXIS Health. The successful... |
More articles from Worldwide Biotech
MIRCERA GETS POSITIVE OPINION IN EUROPE FOR ANAEMIA., July 01, 2007
S*BIO/UNIVERSITY OF SINGAPORE PARTNER ON TUMOR BIOAMARKER., July 01, 2007
ONCOLYTICS BIOTECH GETS 21ST U.S. PATENT., July 01, 2007
Looking for additional articles?
Click here
to search our database of over 3 million articles.
|
